Plain language summary of a study looking at heart muscle thickness and kidney function in women with Fabry disease who received agalsidase beta treatment
Related Experiment Video
Updated: Aug 29, 2025
In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Christoph Wanner1, Ulla Feldt-Rasmussen2, Alberto Ortiz3
1Department of Medicine, Division of Nephrology, University Hospital Würzburg, Würzburg, Germany.
Insights
Agalsidase beta treatment slowed heart muscle thickening in women with Fabry disease. Kidney function remained stable in treated women, suggesting potential benefits for this rare genetic condition.
Area of Science:
- Genetics and rare diseases
- Cardiovascular and renal medicine
- Enzyme replacement therapy
Background:
- Fabry disease is a rare genetic disorder caused by mutations in the GLA gene, leading to deficient alpha-galactosidase activity.
- This deficiency results in the accumulation of glycolipids, particularly affecting the heart, kidneys, and nervous system.
- While Fabry disease affects both sexes, its impact and treatment effects in women are less studied than in men.
Purpose of the Study:
- To evaluate the long-term effects of agalsidase beta enzyme replacement therapy (ERT) on cardiac and renal parameters in adult women with Fabry disease.
- To assess changes in heart muscle thickness and kidney function before and after initiating agalsidase beta treatment.
Main Methods:
- Utilized data from the Fabry Registry, a comprehensive global database for individuals with Fabry disease.
- Analyzed cardiac (heart muscle thickness) and renal (kidney function) data from women diagnosed with Fabry disease who began agalsidase beta treatment at age 18 or older.
- Compared parameters from 5 years prior to treatment initiation to 5 years post-treatment.
Main Results:
- Women with Fabry disease showed a trend of increasing heart muscle thickness prior to treatment.
- Agalsidase beta treatment was associated with a slowing of heart muscle thickening.
- Kidney function in these women remained comparable to unaffected individuals both before and after treatment.
Conclusions:
- Agalsidase beta therapy may help mitigate cardiac complications, specifically left ventricular hypertrophy, in women with Fabry disease.
- The findings suggest that agalsidase beta can help maintain normal kidney function in adult women with this genetic condition.
- This study offers valuable insights into the efficacy of agalsidase beta in the female population, highlighting its potential role in managing Fabry disease progression.
What Is Fabry Disease & What Is This Study About?:
Fabry disease is a rare genetic condition that affects many different cells and organs in the body. People have Fabry disease when they inherit a GLA gene containing an error from one or both of their parents. This causes an enzyme in their body called alpha-galactosidase (also called α-Gal) to not work properly. In people without Fabry disease, a-Gal breaks down fats called glycolipids. In people with Fabry disease, as a-Gal does not work properly, glycolipids build up in the body, particularly in the cells of the kidney, heart, nerves, and the cells that line blood vessels. People who have Fabry disease can receive an enzyme replacement therapy (ERT for short) called agalsidase beta, which acts as a substitute for a-Gal. Although both males and females can have Fabry disease, it generally affects males more severely than females, and symptoms in females can vary significantly. Several researchers have studied the long-term effects of agalsidase beta ERT in males, but there have been fewer studies in females. This study looked at women with Fabry disease who started receiving agalsidase beta treatment when they were at least 18 years old, using information from the Fabry Registry (the largest worldwide database that collects and stores information about people with Fabry disease). The researchers evaluated heart muscle thickness (thickening can be a sign of poor heart health) and kidney function from 5 years before women with Fabry disease started agalsidase beta treatment to 5 years after they started treatment.
What Were The Study Results?:
Before women with Fabry disease started treatment, their heart muscle tended to thicken over time. After starting treatment, their heart muscle thickening slowed. Kidney function was similar to that of unaffected people both before and after treatment.
What Do The Results Of The Study Mean?:
This study provides a unique insight into the effects of agalsidase beta in women with Fabry disease. The findings suggest that agalsidase beta may slow heart muscle thickening and maintain normal kidney function in women with Fabry disease. Clinical Trial Registration: NCT00196742 (ClinicalTrials.gov).
